Is CGEN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

402 people get CGEN articles and Market Currents by email alert.

Get email alerts on CGEN »

HEADLINES:

Compugen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25 • 9 Comments
Compugen Ltd. Reports First Quarter 2013 Financial Results

Business Wire (Apr 25, 2013)
Compugen to Present at the 12th Annual Needham Healthcare Conference

Business Wire (Apr 23, 2013)
Compugen First Quarter 2013 Conference Call Scheduled for Thursday, April 25, 2013 at 10:00 AM EDT

Business Wire (Apr 18, 2013)
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

Business Wire (Apr 17, 2013)
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

Business Wire (Apr 2, 2013)
Compugen's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
Compugen Ltd. Reports Fourth Quarter and Calendar 2012 Financial Results

Business Wire (Feb 20, 2013)
CORRECTING and REPLACING Compugen Fourth Quarter 2012 Conference Call Scheduled for Wednesday, February 20, 2013 at 10:00 AM EST

Business Wire (Feb 12, 2013)
Compugen to Present at the Molecular Medicine Tri-Conference 2013 in San Francisco

Business Wire (Feb 5, 2013)
Compugen Presents at American Association of Cancer Research Special Conference on Tumor Immunology

Business Wire (Dec 4, 2012)
Show Me The Money: ADC Revenue Payloads Miss The Mark
Michael Webb • Mon, Nov 26, 2012 • 20 Comments
Compugen Announces $15 Million Funding Agreement for Its Keddem Subsidiary

Business Wire (Nov 19, 2012)
Compugen to Present at Jefferies 2012 Global Healthcare Conference

Business Wire (Nov 14, 2012)
Compugen's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 5, 2012
Compugen Ltd. Reports Third Quarter 2012 Financial Results

Business Wire (Nov 5, 2012)
Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy

Business Wire (Oct 31, 2012)
Compugen Postpones Issuance of Third Quarter 2012 Report and Associated Conference Call to November 5, 2012, Due to Expected Severe Weather Conditions

Business Wire (Oct 29, 2012)
Compugen Third Quarter 2012 Conference Call Scheduled for Tuesday, October 30, 2012 at 10:00 AM EDT

Business Wire (Oct 23, 2012)
Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance

Business Wire (Sep 10, 2012)

To learn more about Seeking Alpha Pro, click here.

Compugen Goes the Extra Mile in Drug Discovery
Prohost Biotech • Fri, Aug 13, 2010 • 1 Comment
Compugen: On the Road to Breakthroughs
Prohost Biotech • Wed, May 12, 2010 • 1 Comment

Show Me The Money: ADC Revenue Payloads Miss The Mark
Michael Webb • Mon, Nov 26, 2012 • 20 Comments
What's Driving Stocks Tuesday: ECB And Fed Hope And Fumes
Markos Kaminis • Tue, Aug 7, 2012 • 3 Comments
Bear Raids And Tree Shaking In Biotechnology And Drugs
Joe Springer • Tue, Aug 7, 2012 • 13 Comments
6 Micro-Cap Biotech Stocks Enjoying Winning Streaks
Kapitall • Thu, Aug 25, 2011 • 1 Comment
9 Biotech Stocks for 2011
Michael Shulman • Thu, Jan 13, 2011 • 31 Comments
Global Marketplace Activity: China IPOs, Israel M&A, Bank Bond Update
Global Investing Editor • Wed, Jan 5, 2011
Life Sciences Companies Raise Record Amounts of Capital
The Burrill Report • Fri, Dec 31, 2010
15 Biotech Stocks With the Lowest Put/Call Ratios
Kapitall • Wed, Oct 13, 2010 • 3 Comments
Healthcare Reform and the Bottom Line
Michael Shulman • Mon, Mar 22, 2010 • 111 Comments
CompuGen-Pfizer Deal: What Biotech 'Dreamers' Can Accomplish
Prohost Biotech • Thu, Dec 24, 2009 • 7 Comments
Closing Update for July 29, 2009: Modestly Red
Midnight Trader • Wed, Jul 29, 2009 • 2 Comments
Short Term Swine Flu Trades
Dr. Kris • Tue, Apr 28, 2009 • 2 Comments
Biotech Day in Review: Avalon Signs $200 Million Deal with Merck
Centient Biotech Investor • Thu, Mar 8, 2007
Compugen-Teva Deal: Lessons For Investors
Shlomo Greenberg • Thu, Feb 1, 2007
Biotech Stocks Day In Review: Alfacell Receives Orphan Drug Status For Onconase
Centient Biotech Investor • Wed, Jan 31, 2007
Biotech Week-in-Review: Genentech, Amgen Take a Toll on Biotech
Centient Biotech Investor • Mon, Jan 29, 2007
Biotech Stocks Day-In-Review: Coley Drops After Ending Hepatitis C Program
Centient Biotech Investor • Wed, Jan 24, 2007

Compugen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25 • 9 Comments
Compugen's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
Compugen's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 5, 2012
Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012

Compugen Ltd. Reports First Quarter 2013 Financial Results

Business Wire (Apr 25, 2013)
Compugen to Present at the 12th Annual Needham Healthcare Conference

Business Wire (Apr 23, 2013)
Compugen First Quarter 2013 Conference Call Scheduled for Thursday, April 25, 2013 at 10:00 AM EDT

Business Wire (Apr 18, 2013)
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

Business Wire (Apr 17, 2013)
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

Business Wire (Apr 2, 2013)
Compugen Ltd. Reports Fourth Quarter and Calendar 2012 Financial Results

Business Wire (Feb 20, 2013)
CORRECTING and REPLACING Compugen Fourth Quarter 2012 Conference Call Scheduled for Wednesday, February 20, 2013 at 10:00 AM EST

Business Wire (Feb 12, 2013)
Compugen to Present at the Molecular Medicine Tri-Conference 2013 in San Francisco

Business Wire (Feb 5, 2013)
Compugen Presents at American Association of Cancer Research Special Conference on Tumor Immunology

Business Wire (Dec 4, 2012)
Compugen Announces $15 Million Funding Agreement for Its Keddem Subsidiary

Business Wire (Nov 19, 2012)
Compugen to Present at Jefferies 2012 Global Healthcare Conference

Business Wire (Nov 14, 2012)
Compugen Ltd. Reports Third Quarter 2012 Financial Results

Business Wire (Nov 5, 2012)
Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy

Business Wire (Oct 31, 2012)
Compugen Postpones Issuance of Third Quarter 2012 Report and Associated Conference Call to November 5, 2012, Due to Expected Severe Weather Conditions

Business Wire (Oct 29, 2012)
Compugen Third Quarter 2012 Conference Call Scheduled for Tuesday, October 30, 2012 at 10:00 AM EDT

Business Wire (Oct 23, 2012)
Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance

Business Wire (Sep 10, 2012)
Compugen Ltd. Reports Second Quarter 2012 Financial Results

Business Wire (Aug 7, 2012)
Compugen Second Quarter 2012 Conference Call Scheduled for Tuesday, August 7, 2012 at 10:00 AM EDT

Business Wire (Jul 30, 2012)
Compugen Announces Development of NexGen Infrastructure Platform for Analysis of Next Generation Sequencing Data

Business Wire (Jul 2, 2012)
Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy

Business Wire (Jun 27, 2012)

CGEN vs. ETF Alternatives

Company Description

Currently, there's no company description for CGEN.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, February 2, 2012, 8:01 AM Shares of Compugen (CGEN) move up 6.9% in premarket trading after the firm announces that its CGEN-15001T cancer drug demonstrates "significant potential" for cancer immunotherapy. The firm says it ran studies using an antibody specifically recognizing CGEN-15001T. Comment! [On the Move, Healthcare]
Tuesday, December 20, 2011, 11:34 AM Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody program and will establish preclinical development capabilities in-house instead of using third parties. The firm will take on $8M in funding from Israel-based Baize Investments to help move along its research program. Comment! [Healthcare, On the Move]
Tuesday, March 16, 2010, 9:05 AM Premarket gainers: CGEN +10%. ANPI +8%. ATHN +8%. MPEL +7%. CTIC +5%. DNN +5%. OFG +4%. GKK +4%. PDC +4%. MNKD +4%.
Losers: SQNM -18%. LXRX -13%. GEL -6%. GLP -6%. GSI -4%. Comment!
Tuesday, February 2, 2010, 11:12 AM Shares of Compugen (CGEN) are up more than 10% after the Israeli biotech company said it discovered a new protein for the treatment of autoimmune disorders. The new protein (CGEN-15001) is the extracellular region of a new membrane protein, and could potentially be used to treat MS, rheumatoid arthritis, inflammatory bowel disease and type 1 diabetes. Comment!
Tuesday, February 2, 2010, 9:00 AM Premarket gainers: CITP +32%. BKS +16%. CGEN +16%. LXK +15%. ANN +12%. CBAK +8%. EMR +8%. ARMH +7%. DHI +7%. TI +6%. IVAN +6%. CMI +5%. COCO +5%. BEXP +5%. HOLX +4%. Q +5%.
Losers: TUES -8%. PLX -5%. BP -5%. AMSC -4%. DST -4%. OKS -4%. Comment!
Monday, January 4, 2010, 9:00 AM Premarket gainers: BFRM +61%. IRE +13%. AIB +9%. IDN +7%. TSEM +6%. ING +6%. ALU +6%. LPL +6%. CHK +5%. TSO +5%. EXXI +5%. UNG +5%. CGEN +5%. STEC +5%. VLNC +4%. AU +4%. WYNN +4%. LVS +4%. MS +4%. TTM +4%. TEN +4%. PAL +4%. LYG +4%. CS +4%. MT +4%.
Losers: ACL -4%. Comment!
Wednesday, December 30, 2009, 9:00 AM Premarket gainers: OSIS +7%. CGEN +5%.
Losers: CBAK -23%. FNM -5%. FRE -5%. AIB -4%. Comment!
Monday, December 28, 2009, 9:05 AM Compugen (CGEN), which last week signed a big collaboration deal with Pfizer (PFE), is up 34% premarket after announcing the discovery and experimental validation of a new drug target for multiple epithelial tumors, whose carcinomas account for approximately 85% of all cancers. Comment!
Monday, December 28, 2009, 9:00 AM Premarket gainers: CGEN +34%. AMCS +28%. FRE +25%. FNM +21%. VICL +19%. SVA +9%. KEP +8%. DPTR +5%. MBI +5%. PMI +5%. ABK +4%. AIG +4%.
Losers: CHT -5%. Comment!
Wednesday, December 23, 2009, 10:21 AM Early gainers:
- Compugen (CGEN +83%) announces collaboration with Pfizer (PFE) on therapeutic peptide product candidates.
- FSI International (FSII +17%) strong FQ1 earnings.
- Ballard Power Systems (BLDP +13%) chosen to supply Daimler (DAI) with fuel cell products. Comment!
Wednesday, December 23, 2009, 9:00 AM Premarket gainers: PSDV +65%. CGEN +65%. BLDP +17%. TIBX +7%. STEM +7%. RHT +6%. TSEM +5%. IOC +4%.
Losers: MTG -3%. Comment!

Michael Webb
$CGEN I've grown skeptical again of this company. Where's the evidence that their science will translate into products of value?
Mar 25, 4:22 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Eisenberg
Any thoughts on why $CGEN had a big move today?
Mar 11, 4:28 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Eisenberg
Anyone know why $CGEN is moving? Up 10% today and 25% in last ~month. (FD: I am long $CGEN)
12/13/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Primarily because of their inclusion on the two Israeli stock exchanges but also because of their announcement of 30 compounds to develop.
12/14/12
• !Report Abuse
Add a reply...

140 characters

Michael Webb
$CGEN Up 18.37% in the past 2 Weeks. Umm, that's a good taste!
11/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Eisenberg
I am long CGEN, liking my trade & staying long http://bit.ly/y4PDQ0
2/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
$CGEN another strong breakout today. $ECIT topping. $PROT short taking profits.
2/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Eisenberg
Agree with The Fool on CGEN. Also big upside from evogene holding. FD: very long CGEN http://bit.ly/k8tjJK
6/23/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
ARIA, DCTH, GERN, INCY, CGEN, => Notable Developments and Results 12/6/10 => Rx Investors.com => http://bit.ly/c9Kc5C
12/6/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ki2
Holding AMZN. Increased AAPL by 7%. Buying CGEN aggressively.
12/27/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ki2
Still holding my AMZN. Increased AAPL stake by 7%. Buying CGEN aggressively as big news to come.
12/26/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Michael Eisenberg
Anyone know why $CGEN is moving? Up 10% today and 25% in last ~month. (FD: I am long $CGEN)
12/13/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Primarily because of their inclusion on the two Israeli stock exchanges but also because of their announcement of 30 compounds to develop.
12/14/12
• !Report Abuse
Add a reply...

140 characters

CGEN Compugen Ltd.

CGEN

Compugen Ltd.